IL145585A0 - A process for preparing 1-phenyl-2-(2-pyridyl) ethanamine - Google Patents

A process for preparing 1-phenyl-2-(2-pyridyl) ethanamine

Info

Publication number
IL145585A0
IL145585A0 IL14558500A IL14558500A IL145585A0 IL 145585 A0 IL145585 A0 IL 145585A0 IL 14558500 A IL14558500 A IL 14558500A IL 14558500 A IL14558500 A IL 14558500A IL 145585 A0 IL145585 A0 IL 145585A0
Authority
IL
Israel
Prior art keywords
ethanamine
pyridyl
phenyl
preparing
preparation
Prior art date
Application number
IL14558500A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL145585A0 publication Critical patent/IL145585A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
IL14558500A 1999-04-15 2000-04-14 A process for preparing 1-phenyl-2-(2-pyridyl) ethanamine IL145585A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901340A SE9901340D0 (sv) 1999-04-15 1999-04-15 Novel process
PCT/SE2000/000713 WO2000063175A2 (en) 1999-04-15 2000-04-14 Novel process

Publications (1)

Publication Number Publication Date
IL145585A0 true IL145585A0 (en) 2002-11-10

Family

ID=20415222

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14558500A IL145585A0 (en) 1999-04-15 2000-04-14 A process for preparing 1-phenyl-2-(2-pyridyl) ethanamine
IL145585A IL145585A (en) 1999-04-15 2001-09-24 Process for preparing 1-phenyl-2-(2-pyridyl) ethanamine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL145585A IL145585A (en) 1999-04-15 2001-09-24 Process for preparing 1-phenyl-2-(2-pyridyl) ethanamine

Country Status (18)

Country Link
US (1) US6518432B1 (no)
EP (1) EP1492769B1 (no)
JP (1) JP4676064B2 (no)
KR (1) KR100663811B1 (no)
CN (1) CN1138759C (no)
AT (1) ATE333444T1 (no)
AU (1) AU773962B2 (no)
BR (1) BR0009795B1 (no)
CA (1) CA2367410C (no)
DE (1) DE60029493T2 (no)
ES (1) ES2267526T3 (no)
IL (2) IL145585A0 (no)
NO (1) NO320810B1 (no)
NZ (1) NZ514586A (no)
SE (1) SE9901340D0 (no)
TW (1) TWI248433B (no)
WO (1) WO2000063175A2 (no)
ZA (1) ZA200108374B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006680A (es) * 2008-12-24 2011-07-12 Astrazeneca Ab Compuestos etanaminicos y su uso para tratar la depresion.
TR201909632T4 (tr) 2013-11-05 2019-07-22 Astrazeneca Ab Nmda antagonisti ön ilaçları.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US5455259A (en) * 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
EP0540318A1 (en) * 1991-10-30 1993-05-05 Fisons Corporation 2-Heterocyclicethylamine derivatives and their use as pharmaceuticals
SG47948A1 (en) 1992-04-03 1998-04-17 Astra Ab Compounds for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
AU4444700A (en) 2000-11-02
ES2267526T3 (es) 2007-03-16
CN1370145A (zh) 2002-09-18
ATE333444T1 (de) 2006-08-15
DE60029493T2 (de) 2007-01-11
NO20014889L (no) 2001-10-08
ZA200108374B (en) 2003-08-06
SE9901340D0 (sv) 1999-04-15
IL145585A (en) 2006-12-31
EP1492769B1 (en) 2006-07-19
WO2000063175A2 (en) 2000-10-26
DE60029493D1 (de) 2006-08-31
KR100663811B1 (ko) 2007-01-03
AU773962B2 (en) 2004-06-10
US6518432B1 (en) 2003-02-11
BR0009795A (pt) 2002-01-08
JP2003524625A (ja) 2003-08-19
TWI248433B (en) 2006-02-01
KR20010113799A (ko) 2001-12-28
EP1492769A2 (en) 2005-01-05
WO2000063175A3 (en) 2004-11-11
CA2367410C (en) 2009-08-11
JP4676064B2 (ja) 2011-04-27
BR0009795B1 (pt) 2011-12-27
NO320810B1 (no) 2006-01-30
CN1138759C (zh) 2004-02-18
CA2367410A1 (en) 2000-10-26
NO20014889D0 (no) 2001-10-08
NZ514586A (en) 2003-09-26

Similar Documents

Publication Publication Date Title
PL343771A1 (en) N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
YU26602A (sh) Indolinon supstituisan na poziciji 6, njegovo dobijanje i njegova primena kao leka
SG147286A1 (en) Manufacture of polyglumate-therapeutic agent conjugates
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
YU61103A (sh) Postupci za produkciju supstituisanih 2-(2-piridilmetil) sulfinil-1h-benzimidazola
NZ515304A (en) Bradykinin receptor antagonists
WO2001032631A3 (en) Heterocyclic cytotoxic agents
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
JO2252B1 (en) Method for preparing pyridine derivatives
NZ513041A (en) N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists; their preparation and medicaments containing them
BG105766A (en) New process for preparing pesticidal intermediates
IL146811A0 (en) Novel method for preparing benzoperhydroisoindole compounds
BG106002A (en) Process for preparing pesticidal intermediates
IL145585A0 (en) A process for preparing 1-phenyl-2-(2-pyridyl) ethanamine
WO2002072567A3 (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
MXPA02009210A (es) Modificacion amorfa de torasemida.
AU2001278908A1 (en) Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido(2,3-d)pyrimidin 7-ones
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
IL148161A0 (en) Process for the preparation of 2-cyanopyridines
AU6870600A (en) Process for the preparation of 2,3-dihydroazepine compounds
SE9901338D0 (sv) Novel process
HRP20020021B1 (en) Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates
IN184757B (no)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed